3
Human genetic, biochemical and pharmacologic evidence implicates rate-limiting transthyretin (TTR) tetramer dissociation, followed by rapid monomer misfolding and misassembly, as the cause of several degenerative diseases exhibiting overlapping phenotypes, collectively referred to as the transthyretin amyloidoses.
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The amyloidogenic TTR monomer misassembles into a variety of aggregate structures during amyloidogenesis, including cross-β-sheet amyloid fibrils, for which these diseases are named. [17] [18] [19] Amyloidogenesis of wild-type (WT) TTR or aggregation of certain mutants along with WT-TTR in heterozygotes leads to cardiomyopathies, affecting up to 500,000 individuals (disorders historically called senile systemic amyloidosis (SSA) and familial amyloid cardiomyopathy (FAC), respectively).
14, 20 Amyloidogenesis of distinct TTR mutants along with WT-TTR in heterozygotes results in a primary autonomic and peripheral neuropathy, often called familial amyloid polyneuropathy (FAP) . The latter disease has historically been treated by liver transplant-mediated gene therapy, wherein the mutant-TTR / WT-TTR liver (which secretes destabilized TTR heterotetramers) is replaced by a WT-TTR / WT-TTR liver (which secretes a more stable WT-TTR homotetramer).
Interestingly, slowing the course of peripheral disease progression by liver transplantation has led to the appearance of TTR aggregation in the central nervous system (CNS) and eyes, which manifests as a consequence of treatment-associated lifespan extension. [21] [22] [23] [24] [25] [26] Another strategy to prevent TTR amyloidogenesis is to fashion small molecules that bind selectively in human blood to one or both of the thyroxine (T 4 ) binding sites comprising the tetramer made up of WT or mutant and WT subunits. Selective binding to the native tetrameric ground state of TTR over the dissociative transition state raises the kinetic barrier for subunit dissociation, substantially slowing TTR aggregation. The extent of kinetic stabilization of tetrameric TTR determines the extent to which amyloidogenesis is inhibited. [27] [28] [29] [30] [31] A placebo-4 controlled clinical trial in V30M FAP patients (a prominent mutation causing tetramer destabilization), along with a 12-month extension study, demonstrates the efficacy of this strategy in slowing the progression of autonomic and peripheral neuropathy. 32, 33 Our studies carried out over the last two decades to develop small molecule TTR amyloidogenesis inhibitors have revealed that optimal TTR kinetic stabilizers are typically composed of two aryl rings joined by linkers of variable chemical composition. 28, 29, Figure   S1 and Table S1 in the Supporting Information contain compilations of the structures and experimental results for the majority of the inhibitors procured or synthesized by the Kelly laboratory during this period. Binding of these small molecules to one or both of the generally unoccupied, funnel-shaped, T 4 binding pockets strengthens the weaker dimer-dimer interface of TTR by non-covalently bridging adjacent monomeric subunits through specific hydrophobic and electrostatic interactions, as exemplified in the TTR•(201) 2 crystal structure (Figure 1) . To gauge the efficacy of candidate molecules to bind to the T 4 pockets and kinetically stabilize the TTR tetramer from dissociating and aggregating in complex biological environments, we rely on two primary assays: 1) an in vitro acid-mediated TTR aggregation assay carried out with recombinant TTR in buffer; and 2) an ex vivo TTR immunoprecipitation / HPLC assay to quantify the stoichiometry of a candidate kinetic stabilizer bound to TTR in blood plasma. These two assays are briefly explained below, with complete experimental details presented in the Supporting Information).
56, 57
Figure 1: X-ray structure of the TTR•(201) 2 complex (PDB ID 5TZL) highlights the interactions known to be important for tight binding to TTR. Compound 201 is bound in its equivalent symmetry-related binding modes (grey and green, respectively), which results from ligand binding along the crystallographic 2-fold axis. The omit F O -F C density (contoured at +/-3.5ો) for 201 is shown in Figure S3 of the Supporting Information. The binding pocket is characterized by a smaller inner cavity and a larger outer cavity, throughout which are distributed three pairs of symmetric hydrophobic depressions, referred to as the halogen binding pockets (HBPs ultimately showed that treatment with diflunisal reduces the rate of progression of neurological impairment and preserves the quality of life in polyneuropathy patients. 59 However, the long term therapeutic use of diflunisal for the treatment of the transthyretin amyloidoses is limited by the fact that, as an NSAID, it can trigger gastrointestinal bleeds and impair renal flow, [59] [60] [61] [62] [63] [64] which is already diminished in cardiomyopathy patients. Hence, diflunisal is contraindicated for TTR cardiomyopathy patients. Thus, we focused on developing lead TTR kinetic stabilizers / amyloidogenesis inhibitors that did not inhibit cyclooxygenase activity.
Early on in our TTR kinetic stabilizer development program, it became clear that some of the most potent TTR kinetic stabilizers under evaluation also exhibited binding to the thyroid hormone receptors, which would likely produce undesirable metabolism and heart rate sideeffects in the envisioned long-term use of TTR amyloidogenesis inhibitors. Thus, we also sought TTR kinetic stabilizers that were neither thyroid agonists nor antagonists. Unfortunately, a drawback to current therapies is that a subset of liver transplant patients with FAP, and some tafamidis-treated patients, present with continued ocular and CNS deposition of TTR aggregates (tafamidis does not enter the eye or the brain upon oral administration). It seems that the majority of FAP patients treated by liver transplant-mediated gene therapy develop CNS amyloid pathology after more than a decade of treatment. Thus, it may be necessary to develop a second generation, tafamidis-like molecule that enters the eye and the brain while still maintaining TTR kinetic stabilization in the periphery.
To increase the success of developing second generation transthyretin kinetic stabilizers / amyloidosis inhibitors, in the present study, we have developed two semi-quantitative models to predict the structures of potent TTR kinetic stabilizers / amyloidogenesis inhibitors that bind with high selectivity to TTR in the blood, and that exhibit minimal off-target effects, such as binding to the thyroid hormone receptor or the cyclooxygenase enzymes. The development of these two prediction models will allow us to more effectively focus future research efforts on optimizing the CNS and ocular permeability of TTR kinetic stabilizers, since we can be 9 confident that, even before any synthesis commences, proposed lead candidates will have a high probability of selectively targeting transthyretin.
Figure 2.
Summary of the structure-activity relationships (data derived) from a trio of previous libraries designed to screen the three substructures of a typical small molecule TTR amyloidosis inhibitor (i.e., Aryl-X, Linker-Y, and Aryl-Z). [46] [47] [48] Substructures are quantitatively ranked according to the average experimental efficacy scores (EES) as determined using Equation 1, which evaluates the ability of a substructure to afford potent aggregation inhibitors in vitro that bind selectively to TTR in human blood plasma ex vivo.
Previously, we synthesized and evaluated three libraries of TTR kinetic stabilizer candidates in an effort to optimize the three substructures of a typical TTR amyloidogenesis inhibitor -the two aromatic rings and the linker joining them ( Figure S1, compounds 1-134) . [46] [47] [48] The structure-activity relationship (SAR) data from these three mini-libraries (detailed in the 10 previous studies and summarized in Figure 2 ) [46] [47] [48] were envisioned to contain the information enabling one to predict the potency and selectivity of a larger combinatorial library of "theoretical" TTR amyloidogenesis inhibitors. For the envisioned predictive algorithm, Equation 1 was developed, incorporating an equal weighting of inhibitor potency (based on % FF) and plasma TTR binding selectivity (PS), to semi-quantitatively rank compounds by what we call an Experimental Efficacy Score (EES).
Equation 1
EESs range from 0 (least potent and selective inhibitors) to a maximum of 1, which corresponds to a compound displaying maximal amyloidogenesis inhibition (0% FF) and a maximum binding Prior to the creation of the fourth library, the stilbene and dihydrostilbene library, 49 emerging evidence from a panel of compounds designed to validate this lead candidate predictive algorithm (compounds 200-218 and others that were later incorporated into the stilbene and dihydrostilbene scaffold) suggested that molecules at the high end of the PES range stood a greater chance of binding to the TH nuclear receptor. However, it appeared that investigating compounds with sub-optimal PES values could alleviate this issue. To probe what appeared to be the transition zone from low-to-high TH receptor binding, we investigated the stilbene and dihydrostilbene compound series. The area shaded grey represents the PES region where significant enrichment of molecules below this cutoff occurs: that is, where the greatest proportion of highly desirable molecules that do not bind to the TH receptor are predicted (PES < 2.5). Please refer to Table S1 in the Supporting Information for a complete tabulation of all values.
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Given that the most promising clinical candidates are not necessarily those with the highest Predicted Efficacy Scores, we reassessed the scoring algorithm to incorporate a "negative design" component, i.e., to select against compounds exhibiting TH receptor binding capacity.
Toward this end, the Experimental Efficacy Scoring function of Equation 1 was modified to integrate relative TH receptor binding results and compute what we refer to as a Thyroid
Hormone Receptor Experimental Efficacy Score, or THREE Score (Equation 3).
Equation 3
‫ܧܧܴܪܶ‬ ‫݁ݎܿܵ‬ = ሺ100% − ‫‪ሻ‬ܨܨ%‬ × ሺ1 + ܲܵሻ 300% − ܴ݈݁. ‫ܴܪܶ‬ Figures 3 and 4 , plotting THREE Scores as a function of PES ( Figure 5) demonstrates an enrichment of compounds that exceed the 0.667 threshold within the 1.8-2.5
Consistent with data in
PES range (shaded area), with a maximum occurring at a PES of ~2.2 (refer to Table S1 in the Supporting Information for a tabulation of all THREE Score results). . The cutoff line at 0.667 represents 1 inhibitor bound per TTR tetramer as described in Figure 3 . Solid black data points represent the percentage of compounds within the 0.2 PES bins that exceed the 0.667 cutoff. As in Figure 3 , the highest proportion of potent and selective TTR aggregation inhibitors occurs at PES values >1.8; however, at PES values above 2.5, binding to the TH receptor decreases the THREE score values significantly. Thus, the most promising potent and selective TTR amyloidogenesis inhibitors that display minimal binding to the TH receptor are predicted in the PES=1.8-2.5 range (i.e., the area shaded grey). Please refer to Table S1 in the Supporting Information for a complete tabulation of all values.
While these Predicted Efficacy Scores are useful for identifying candidate TTR kinetic stabilizers, this semi-quantitative optimization algorithm has several deficiencies that limit its effectiveness. For one, this algorithm is limited to predicting the efficacies of compounds encompassed within the scope of the scaffold substructures included in the Aryl-X, Aryl-Z, and
Linker-Y optimization studies (i.e., limited to the substructures presented in Figure 2 ). [46] [47] [48] Furthermore, PES calculations can be ambiguous owing to molecular symmetry that does not permit unambiguous assignment of Aryl-X and Aryl-Z rings; thus, scoring in both directions is possible, which may not give the same PES values (this issue is described in more detail with compound 88 in Figure S2B of the Supporting Information). Scaffolds such as the benzoxazoles, featuring substituent patterns that do not fall within the general classification of ortho, meta, and para, also complicate PES calculations. PES comparisons are further complicated by the differences in linker lengths and angles between the aryl rings (e.g., biphenyls vs. a urea linker vs. a biphenyl ether linker, etc.), distinctions in substituent orientation on different scaffolds, and the orientation differences of the candidate kinetic stabilizers within the TTR T 4 binding sites, which this algorithm assumes are equivalent. We also note that carboxylates were not highly represented in the three mini-libraries that serve as the basis for this strategy. [46] [47] [48] In prior SAR studies, carboxylate-bearing aryls strongly favor binding to the outer cavity of the T 4 binding site. However, in one of the mini-libraries, 48 a 3,5-Br 2 -4-OH aryl-X group was employed that preferred binding in the outer cavity; thus, the carboxylates on the aryl-Z ring were unfavorably positioned into the inner binding cavity, leading to their assignment of low Z s scores. We know that for many inhibitors, carboxylates are not as much of a liability as this scoring algorithm would suggest. This deficiency is highlighted by the results of tafamidis (compound 250), which, while proving to be an excellent drug for treating FAP, would not have been predicted as a lead candidate using this algorithm: PES = 1.558, EES = 0.597, and THREE Score = 0.597.
Thus, if we had evaluated a larger data set, carboxylate substituents might have been suggested as more favorable and tafamidis would likely have fallen within the 1.8-2.5 PES range for optimal candidates to select for further pre-clinical and clinical evaluation.
To counter the deficiencies inherent in the PES algorithm described above, we evaluated the viability of an in silico docking model for predicting the efficacy of TTR kinetic stabilizers.
In this approach, we obtained docking energies for all of the compounds listed in Figure S1 and Table S1 by docking them to the unliganded TTR derived from the TTR•(201) 2 complex 18 structure using AutoDock 4.
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We used the apo-TTR from the TTR•(201) 2 crystal structure because 201 exhibits one of the highest experimental efficacy scores that we have ever observed (EES = 0.97) -the idea being that TTR adopts this structure because of complementarity to an ideal kinetic stabilizer from a TTR binding perspective. The detailed protocol employed for compound docking to TTR is outlined in the Supporting Information. Briefly, compound structures were created using ChemDraw, then their conformational energy was minimized using Accelrys Discovery Studio 4. The compound docking files, the receptor docking files, and docking parameter files were prepared using AutoDockTools 1.5.6. The receptor grid maps were established using the AutoGrid4 program, with a grid box large enough to encompass both of the thyroxine binding sites so that the molecules could dock to either site in a single simulation.
Compounds were then docked in the receptor employing triplicate simulations and the docking conformations and energies were evaluated in AutoDockTools. If the docked conformations were considered reasonable (i.e., bound in conformations that we would expect based on our prior experience observing numerous TTR•(Inhibitor) 2 co-crystal structures, but in general with RMSDs < 8Å -see validation discussion below), the docking energies were recorded in Table   S1 (representing the average of the three docking energies). In 92.2% of the dockings, the lowest energy conformations were considered reasonable and bound in conformations we would expect. For the remaining 7.8% of the dockings, the lowest energy conformations had the molecules either not positioned within the binding site or in conformations that we have not previously observed; however, in all cases, we were able to observe reasonable binding conformations for higher energy docked structures. Therefore, we recorded these higher energy docking conformations in Table S1 , rather than the lowest docking energies for the conformations that were deemed unreasonable. Table S1 ) were plotted against in vitro biochemical results to evaluate potential correlations ( Figure S5 , left panels, in the Supporting Information). for the carboxyl and nitro substituents, respectively. Since we are perturbing these docking energies using correction factors for the -CO 2 H and -NO 2 substituents, we feel that representing the corrected values as energies is not entirely valid, and thus we represent the results as docking "scores" omitting the units (kcal/mol). A detailed description of how we determined these "correction factors" and how they are used to compute corrected docking scores is presented in the Supporting Information.
As with the Predicted Efficacy Scores, we compared the corrected in silico docking scores for all the inhibitors against the various biochemical results and scoring functions ( Figure   7 ). As shown in Figure 7A , the most potent TTR kinetic stabilizers (aggregation inhibitors) in vitro are those with corrected docking scores lower than -7. The corrected docking scores also correlated with the candidate kinetic stabilizer plasma binding stoichiometries ( Figure 7B ) and, consequently, the Experimental Efficacy Scores (Figure 7C ). There was also a trend noted that the lower the corrected docking score, the greater the chance a molecule had for binding to the thyroid hormone receptors (Figure 7D) . From these correlations, it appears that the "sweet spot"
for predicting the most promising lead candidate kinetic stabilizers is associated with a docking score ranging from -7.5 to -9.0 ( Figure 7E) . Perhaps not surprisingly, the corrected docking score for tafamidis is -7.83, which falls within this range. Thus, this in silico optimization algorithm further supports that tafamidis is an excellent transthyretin kinetic stabilizer, a prediction borne out by its clinical efficacy.
While we would like to include a "negative design" component to this in silico algorithm that incorporates scores from docking to the thyroid hormone receptors and cyclooxygenases, the scale of this endeavor renders it beyond the scope of what can be included in the initial paper.
Ideally, we would like more than ten X-ray crystal structures of candidate TTR kinetic stabilizers bound to the thyroid hormone receptors and cyclooxygenases, and these data are lacking. While other thyroid hormone receptor and cyclooxygenase crystal structures are available (i.e. those without TTR kinetic stabilizer ligands), we fear that docking results using these structures may not prove reliable. Future studies linking thyroid hormone receptors and cyclooxygenase cocrystal structures and docking experiments with TTR kinetic stabilizer candidates are warranted to potentially add this negative design component. Areas shaded grey represent the docking score regions where significant enrichment of molecules above the respective cutoffs occur (or below with respect to thyroid hormone receptor binding). In panel E, the greatest proportion of highly desirable, potent, and selective TTR aggregation inhibitors are predicted within the -7.5 to -9.0 docking score region.
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In conclusion, we have developed two semi-quantitative models for predicting the optimal structures of potent and selective transthyretin kinetic stabilizers / amyloidogenesis inhibitors. While in our initial Predicted Efficacy Scoring model, tafamidis fell slightly out of the range for predicting the best lead candidates to pursue for further pre-clinical development, it did fall within the optimized inhibitor zone using our in silico docking model, which we believe is the more robust of the two predictive algorithms. Thus, not only is tafamidis predicted to be a bona fide lead candidate, but the clinical success of tafamidis also supports this algorithm as a useful tool for predicting promising lead transthyretin amyloidogenesis inhibitors for treating the transthyretin amyloidoses. These prediction algorithms should be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate CNS or ophthalmologic challenges caused by TTR aggregation from TTR synthesized by the choroid plexus and the retinal pigment epithelial cells, respectively.
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